All News

21 January 2012

Immunomedics Reports Final Results From Phase Ib/II Study of Yttrium-90-Labeled Clivatuzumab Tetraxetan and Gemcitabine in Advanced Pancreatic CancerAntibodies

21 January 2012

FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk FactorAntibodies

18 January 2012

InflaRx Announces Successful Conduct of Its Clinical Phase I Trial with IFX-1, a New Monoclonal Antibody Inhibiting Complement Driven InflammationAntibodies

13 January 2012

Seattle Genetics Announces Updates to ADCETRIS™ Prescribing InformationAntibodies

13 January 2012

Genentech Announces First Milestone Payment to Device-Maker ForSight VISION4, Inc. in Development of Sustained Delivery LucentisAntibodies

12 January 2012

Three Adimab Antibodies Enter Human Clinical TrialsAntibodies

9 January 2012

Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis StudyAntibodies

9 January 2012

Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer PatientsAntibodies

9 January 2012

Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC TrialAntibodies

9 January 2012

Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy, a Degenerative Neurological DisorderAntibodies

2 January 2012

Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with AbbottAntibodies

30 December 2011

Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancerAntibodies

29 December 2011

Peregrine Provides Update on HCV Clinical ProgramAntibodies

28 December 2011

Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic LeukemiaAntibodies

21 December 2011

XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne VulgarisAntibodies

21 December 2011

Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer’s Disease From MerckAntibodies

21 December 2011

ImmunoGen, Inc. Announces Antibody-Drug Conjugate Collaboration With LillyAntibodies

21 December 2011

UCB Announces Start of the EXXELERATE™ Clinical Study in Rheumatoid ArthritisAntibodies

21 December 2011

MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple SclerosisAntibodies

20 December 2011

Excelimmune Raises $12 Million to Advance Infectious Disease Programs and Expand its Human Recombinant Polyclonal Antibody Platform into Additional Therapeutic AreasAntibodies

20 December 2011

DiaMedica’s DM-204 for Type 2 Diabetes Successfully HumanizedAntibodies

19 December 2011

Selexys Pharmaceuticals Completes Phase I Clinical Study for Sickle Cell DrugAntibodies

17 December 2011

ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 ahead of scheduleAntibodies

17 December 2011

AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer IngelheimAntibodies

15 December 2011

Human Genome Sciences and GlaxoSmithKline Initiate Phase 3 Trial of Belimumab (BENLYSTA®) Administered Subcutaneously in Subjects with Systemic Lupus ErythematosusAntibodies

14 December 2011

Clinical development of BT-062 in multiple myeloma expands into combination therapyAntibodies

14 December 2011

Genentech Initiates First-in-Human Study with NovImmune’s Anti-IL17 AntibodyAntibodies

14 December 2011

Immunomedics Announces Results From Two Clinical Trials at Hematology ConferenceAntibodies

14 December 2011

Profectus BioSciences, Inc. Receives $5.4M Grant to Develop a Monocolonal Antibody Against Infection by Nipah/Hendra VirusesAntibodies

14 December 2011

Seattle Genetics and Millennium Report Data from Phase I Trial of ADCETRIS™ (Brentuximab Vedotin) in Front-line Hodgkin Lymphoma at ASH Annual MeetingAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Ranibizumab (Lucentis) Biosimilars Pipeline Review

CD73 Inhibitor Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective